RU2003133446A - Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения - Google Patents
Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения Download PDFInfo
- Publication number
- RU2003133446A RU2003133446A RU2003133446/15A RU2003133446A RU2003133446A RU 2003133446 A RU2003133446 A RU 2003133446A RU 2003133446/15 A RU2003133446/15 A RU 2003133446/15A RU 2003133446 A RU2003133446 A RU 2003133446A RU 2003133446 A RU2003133446 A RU 2003133446A
- Authority
- RU
- Russia
- Prior art keywords
- carvedilol
- hours
- released
- pharmaceutical composition
- oral pharmaceutical
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 208000019622 heart disease Diseases 0.000 title claims 6
- 201000010099 disease Diseases 0.000 title claims 5
- 230000002265 prevention Effects 0.000 title claims 5
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims 64
- 229960004195 carvedilol Drugs 0.000 claims 64
- 238000000034 method Methods 0.000 claims 12
- 230000036470 plasma concentration Effects 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 238000004090 dissolution Methods 0.000 claims 6
- 239000012530 fluid Substances 0.000 claims 6
- 230000000968 intestinal effect Effects 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000008961 swelling Effects 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920003176 water-insoluble polymer Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Packaging Frangible Articles (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN464MU2001 IN191028B (enExample) | 2001-05-17 | 2001-05-17 | |
| IN464/MUM/2001 | 2001-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003133446A true RU2003133446A (ru) | 2005-03-10 |
Family
ID=11097247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003133446/15A RU2003133446A (ru) | 2001-05-17 | 2002-05-10 | Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030035836A1 (enExample) |
| EP (1) | EP1395258A1 (enExample) |
| JP (1) | JP2004534031A (enExample) |
| KR (1) | KR20040037026A (enExample) |
| CN (1) | CN1525855A (enExample) |
| AU (1) | AU2002314515B2 (enExample) |
| BE (1) | BE1014328A7 (enExample) |
| BR (1) | BR0210976A (enExample) |
| CA (1) | CA2447005A1 (enExample) |
| HU (1) | HUP0400607A3 (enExample) |
| IN (1) | IN191028B (enExample) |
| MX (1) | MXPA03010501A (enExample) |
| PL (1) | PL370589A1 (enExample) |
| RU (1) | RU2003133446A (enExample) |
| WO (1) | WO2002092078A1 (enExample) |
| ZA (1) | ZA200309724B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3024399A (en) | 1998-04-03 | 1999-10-25 | Bm Research A/S | Controlled release composition |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| EP1429734B1 (en) * | 2001-09-21 | 2007-12-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| JP2006500320A (ja) * | 2002-04-30 | 2006-01-05 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール一クエン酸塩一水和物 |
| AU2003248746B2 (en) | 2002-06-27 | 2009-01-08 | Smithkline Beecham (Cork) Limited | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
| US20050261355A1 (en) | 2002-06-27 | 2005-11-24 | Sb Pharmco Puerto Rico Inc., | Carvedilol hydobromide |
| EP1562552A1 (en) * | 2002-11-08 | 2005-08-17 | Egalet A/S | Controlled release carvedilol compositions |
| WO2004047837A2 (en) * | 2002-11-22 | 2004-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-blockers having antioxidant and nitric oxide-donor activity |
| DE602004014747D1 (de) * | 2003-03-26 | 2008-08-14 | Egalet As | Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen |
| EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| ES2335008T3 (es) * | 2003-04-24 | 2010-03-18 | Jagotec Ag | Comprimido con nucleo coloreado. |
| US7260685B2 (en) | 2003-06-20 | 2007-08-21 | Micron Technology, Inc. | Memory hub and access method having internal prefetch buffers |
| EP3395340B8 (en) * | 2003-09-12 | 2019-12-11 | Amgen Inc. | Rapid dissolution formulation of cinacalcet hcl |
| US7120743B2 (en) | 2003-10-20 | 2006-10-10 | Micron Technology, Inc. | Arbitration system and method for memory responses in a hub-based memory system |
| JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
| WO2005051322A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
| US7750036B2 (en) | 2003-11-25 | 2010-07-06 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
| WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| EP1895989A2 (en) * | 2005-06-03 | 2008-03-12 | Egalet A/S | A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids |
| US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
| WO2007144785A2 (en) * | 2006-03-26 | 2007-12-21 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
| SI2049123T2 (sl) | 2006-08-03 | 2016-10-28 | Horizon Pharma Ag | Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida |
| US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
| WO2008070072A2 (en) * | 2006-12-01 | 2008-06-12 | Mutual Pharmaceutical Company, Inc. | Carvedilol forms, compositions, and methods of preparation thereof |
| CA2674536C (en) * | 2007-01-16 | 2016-07-26 | Egalet A/S | Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
| WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
| BRPI0701904A2 (pt) * | 2007-04-27 | 2008-12-09 | Libbs Farmaceutica Ltda | forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica |
| NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| TWI494108B (zh) * | 2009-01-26 | 2015-08-01 | Nitec Pharma Ag | 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途 |
| EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| TWI415604B (zh) * | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | 調控釋放卡菲蒂羅劑型 |
| ES2706880T3 (es) | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
| ES2600894T3 (es) * | 2010-02-22 | 2017-02-13 | Daiichi Sankyo Company, Limited | Preparación sólida de liberación sostenida para uso oral |
| KR20150059167A (ko) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | 제어된 방출을 위한 남용 제지 약학적 조성물 |
| CN104768552A (zh) | 2012-09-03 | 2015-07-08 | 第一三共株式会社 | 含有盐酸氢吗啡酮的口服持续释放药物组合物 |
| KR102241487B1 (ko) | 2013-02-20 | 2021-04-16 | 주식회사 종근당 | 제어방출 펠릿으로 된 약제학적 조성물 |
| KR102158339B1 (ko) | 2016-02-05 | 2020-09-21 | 삼진제약주식회사 | 인습성이 개선된 카르베딜롤 속방성 제제 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815926A1 (de) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| ES2227814T3 (es) * | 1997-03-11 | 2005-04-01 | Arakis Ltd. | Formas de dosificacion que comprenden porciones separadas de enantiomeros r y s. |
| IE970588A1 (en) * | 1997-08-01 | 2000-08-23 | Elan Corp Plc | Controlled release pharmaceutical compositions containing tiagabine |
| US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
| PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
| EP1233768A1 (en) * | 1999-11-15 | 2002-08-28 | Smithkline Beecham | Carvedilol methanesulfonate |
| US6352721B1 (en) * | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
| US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
| AU2001263813A1 (en) * | 2000-04-03 | 2001-10-15 | F.Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
| AU2001297631A1 (en) * | 2000-10-24 | 2002-09-04 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
-
2001
- 2001-05-17 IN IN464MU2001 patent/IN191028B/en unknown
-
2002
- 2002-05-10 PL PL02370589A patent/PL370589A1/xx not_active Application Discontinuation
- 2002-05-10 MX MXPA03010501A patent/MXPA03010501A/es unknown
- 2002-05-10 EP EP02741152A patent/EP1395258A1/en active Pending
- 2002-05-10 CA CA002447005A patent/CA2447005A1/en not_active Abandoned
- 2002-05-10 RU RU2003133446/15A patent/RU2003133446A/ru unknown
- 2002-05-10 HU HU0400607A patent/HUP0400607A3/hu unknown
- 2002-05-10 AU AU2002314515A patent/AU2002314515B2/en not_active Ceased
- 2002-05-10 KR KR10-2003-7014987A patent/KR20040037026A/ko not_active Ceased
- 2002-05-10 WO PCT/IN2002/000118 patent/WO2002092078A1/en not_active Ceased
- 2002-05-10 BR BR0210976-0A patent/BR0210976A/pt not_active IP Right Cessation
- 2002-05-10 CN CNA028101294A patent/CN1525855A/zh active Pending
- 2002-05-10 JP JP2002588995A patent/JP2004534031A/ja active Pending
- 2002-05-16 BE BE2002/0322A patent/BE1014328A7/fr not_active IP Right Cessation
- 2002-08-19 US US10/146,670 patent/US20030035836A1/en not_active Abandoned
-
2003
- 2003-12-15 ZA ZA2003/09724A patent/ZA200309724B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE1014328A7 (fr) | 2003-08-05 |
| HUP0400607A3 (en) | 2005-07-28 |
| CN1525855A (zh) | 2004-09-01 |
| JP2004534031A (ja) | 2004-11-11 |
| KR20040037026A (ko) | 2004-05-04 |
| IN191028B (enExample) | 2003-09-13 |
| MXPA03010501A (es) | 2004-03-02 |
| ZA200309724B (en) | 2005-05-25 |
| CA2447005A1 (en) | 2002-11-21 |
| PL370589A1 (en) | 2005-05-30 |
| BR0210976A (pt) | 2004-10-05 |
| US20030035836A1 (en) | 2003-02-20 |
| EP1395258A1 (en) | 2004-03-10 |
| AU2002314515B2 (en) | 2007-08-16 |
| WO2002092078A1 (en) | 2002-11-21 |
| HUP0400607A2 (hu) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003133446A (ru) | Пероральная фармацевтическая композиция для лечения и профилактики сердечных заболеваний и заболеваний, протекающих с расстройством кровообращения | |
| US4784858A (en) | Controlled release tablet | |
| JPH02209A (ja) | カルビドパ／レボドパの制御放出配合剤 | |
| CA2675724A1 (en) | Oral extended-release composition | |
| EP2405900A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| CN112891546A (zh) | 单独的或与降解分子组合的吸附剂的位置特异性肠内递送 | |
| BRPI9802144B1 (pt) | dispositivo osmótico multicapa aperfeiçoado | |
| CA2304135C (en) | Medicament formulation with a controlled release of an active agent | |
| AU2010258345A1 (en) | Novel pharmaceutical compositions containing pregabalin | |
| KR102479497B1 (ko) | 바레니클린 서방성 제제 및 이의 제조 방법 | |
| BG107372A (bg) | Препарати със забавено действие на хинолонови антибиотици и метод за получаването им | |
| WO2013000578A1 (en) | Controlled release oral dosage form comprising oxycodone | |
| KR20080028361A (ko) | 퀴닌-함유 제어-방출형 제제 | |
| EP3609472A1 (en) | Extended release compositions comprising pyridostigmine | |
| JP2005526739A (ja) | コレステロール濃度を低下させる活性成分を含み、活性成分が遅延放出される薬剤 | |
| WO2004016249A1 (en) | Extended release matrix tablets | |
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| ES2321908T3 (es) | Preparaciones farmaceuticas de liberacion prolongada independientemente del ph. | |
| KR20140121394A (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
| DE60319983T2 (de) | Universelle Zusammensetzung zur kontrollierten Wirkstoffabgabe enthaltend Chitosan | |
| EP1539113A2 (en) | Modified release ketoprofen dosage form | |
| WO2005011666A1 (en) | Stable sustained release oral dosage form of gabapentin | |
| US9561241B1 (en) | Gastroretentive dosage forms for minocycline | |
| US6129931A (en) | Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone | |
| US20070112075A1 (en) | Stable pharmaceutical formulations containing escitalopram and bupropion |